Express Mail Label No: ED 114328712 US Attorney Docket No.: 100936-1P US

100936-1P US

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled:

THERAPEUTIC QUINAZOLINE DERIVATIVES

the spec	eification of which:		
OR	is attached hereto.		
on	was filed on	with Express Mail No.	(Application Number not yet known).
OR		ion Number <u>PCT/GB2003/005640</u>	as United States Application Number or and was amended on
includir		viewed and understand the contents of any amendment referred to above.	f the above-identified specification,
§1.56.	I acknowledge the duty to o	disclose information which is material	to patentability as defined in 37 CFR
applicat	I hereby claim the benefit union(s) listed below:	under Title 35, United States Code, §1	19(e)(1) of any United States provisional
	U.S. Serial No.	Filing Date	Status
matter of Internat acknow of Feder	of any PCT International apple each of the claims of this a ional application in the manuledge the duty to disclose all	plication designating the United State application is not disclosed in the prior ner provided by the first paragraph of a information I know to be material to ich became available between the filing	Title 35, United States Code, §112, I patentability as defined in Title 37, Code
	U.S. Serial No.	Filing Date	Status

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application designating at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Application No.	Filing Date	Priority Claimed
EP	02293240.4	24 December 2002	⊠Yes □No
		(24.12.2002)	

I hereby appoint Heidi Marie Berven (Reg# 48,951), Carol Anne Loeschorn (Reg# 35,590), Christine Catherine McCormack (Limited Recognition Under 37 CFR § 11.9(b)) and Lucy Clare Padget (Limited Recognition Under 37 CFR § 11.9(b)), to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to:

Customer Number 44992

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: MORTLOCK, Andrew, Austen

Inventor's Signature: Andrew Ansten Worthord Date: 13 May 2005

Residence Address: Macclesfield, United Kingdom


Citizenship: GB

- 02

Post Office Address: AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire, SK10 4TG, United

Kingdom

Express Mail Label No: ED 114328712 US Attorney Docket No.: 100936-1P US



BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATES PATENT AND TRADEMARK OFFICE

LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)

Ms. Lucy Clare Padget is hereby given limited recognition under 37 CFR §11.9(b) as an employee of AstraZeneca Pharmaceuticals, LP to prepare and prosecute patent applications wherein the assignee of record is AstraZeneca Pharmaceuticals, LP, and the attorney or agent of record in the applications is a registered practitioner who is an employee of AstraZeneca Pharmaceuticals, LP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Ms. Lucy Clare Padget ceases to lawfully reside in the United States, (ii) Ms. Lucy Clare Padget's employment with AstraZeneca Pharmaceuticals, LP ceases or is terminated, or (iii) Ms. Lucy Clare Padget ceases to remain or reside in the United States on an E-2 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: March 18, 2006

Harry I. Moatz

Director of Enrollment and Discipline